Inflammatory signaling through leukotriene receptors in atherosclerosis

Current Atherosclerosis Reports

Volumn 10, Issue 3, 2008, Pages 244-251

  Bäck, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; ARACHIDONATE 5 LIPOXYGENASE; BAYX 1005; BIIL 284; CARDIOVASCULAR AGENT; CYTOKINE; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LICOFELONE; MATRIX METALLOPROTEINASE; MONTELUKAST; PLACEBO; PRANLUKAST; ROFECOXIB; THEOPHYLLINE; UNCLASSIFIED DRUG; VERLUKAST; AUTACOID; LEUKOTRIENE;

ABDOMINAL AORTA ANEURYSM; ARTERY INTIMA PROLIFERATION; ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOCRINE EFFECT; BINDING AFFINITY; BLOOD VESSEL TONE; CARDIOVASCULAR INFLAMMATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FAT INTAKE; HUMAN; HYPERLIPIDEMIA; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; NONHUMAN; PARACRINE SIGNALING; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD VESSEL; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LEUKOTRIENES; MATRIX METALLOPROTEINASES; RECEPTORS, LEUKOTRIENE;

EID: 42749088012     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0038-7     Document Type: Review

References (49)

1. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007, 357:1841-1854.
2. Allen S, Dashwood M, Morrison K, Yacoub M: Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998, 97:2406-2413.
3. Piomelli D, Feinmark SJ, Cannon PJ: Leukotriene biosynthesis by canine and human coronary arteries. J Pharmacol Exp Ther 1987, 241:763-770.
4. Carry M, Korley V, Willerson JT, et al.: Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992, 85:230-236.
5. Helgadottir A, Manolescu A, Thorleifsson G, et al.: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004, 36:233-239.
6. Bäck M, Hlawaty H, Labat C, et al.: The oral cavity and age: a site of chronic inflammation. PLoS ONE 2007, 2:e1351.
7. Gaber F, James A, Delin I et al.: Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton. J Allergy Clin Immunol 2007, 119:1267-1268.
8. Bäck M, Airila-Månsson S, Jogestrand T, et al.: Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis 2007, 193:389-394.
9. Dwyer JH, Allayee H, Dwyer KM, et al.: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004, 350:29-37.
10. Helgadorrir A, Manolescu A, Helgason A, et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006, 38:68-74.
11. Freiberg JJ, Tybjaerg-Hansen A, Sillesen H, et al.: Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008 (in press).
12. Maznyczka A, Mangino M, Whittaker A, et al.: Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clin Sci (Lond) 2007, 112:411-416.
13. Bäck M: Leukotriene receptors: crucial components in vascular inflammation. Scientific World Journal 2007, 7:1422-1439.
14. Bäck M, Norel X, Walch L, et al.: Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol 2000, 401:389-395.
15. Ciana P, Fumagalli M, Trincavelli ML, et al.: The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006, 25:4615-4627.
16. Bäck M, Bu DX, Bränstrom R, et al.: Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005, 102:17501-17506.
17. Kim N, Luster AD: Regulation of immune cells by eicusanoid receptors. ScientificWorldJournal 2007, 7:1307-1328.
18. Subbarao K, Jala VR, Mathis S, et al.: Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004, 24:369-375.
19. Zhao L, Moos MP, Grabner R, et al.: The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004, 10:966-973.
20. Robertson AK, Rudling M, Zhou X, et al.: Disruption of TGF-beta signaling in T cells accelerates atherusclerosis. J Clin Invest 2003, 112:1342-1350.
21. Bäck M, Sultan A, Ovchinnikova O, Hansson GK: 5-lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007, 100:946-949.
22. Ring WL, Riddick CA, Baker JR, et al.: Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3. J Clin Invest 1996, 97:1293-1301.
23. Aiello RJ, Bourassa PA, Lindsey S, et al.: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002, 22:443-449.
24. Bäck M, Hansson GK: Leukotriene receptors in atherosclerosis. Ann Med 2006, 38:493-502.
25. Mita H, Hasegawa M, Saito H, Akiyama K: Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001, 31:1714-1723.
26. Gronert K, Martinsson-Niskanen T, Ravasi S, et al.: Selectivity of recombinant human leukotriene D4, leukotriene B4, and lipoxin A4 receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001, 158:3-9.
27. Bäck M, Qiu H, Haeggstrom JZ, Sakata K: Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. Am J Physiol Heart Circ Physiol 2004, 287:H419-H424.
28. Sakata K, Dahlén SE, Bäck M: The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. Br J Pharmacol 2004, 141:449-456.
29. Heller EA, Liu E, Tager AM, et al.: Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005, 112:578-586.
30. Kondo K, Umemura K, Ohmura T, et al.: Suppression of intimal hyperplasia by a 5-lipoxygenase inhibitor, MK-886: studies with a photochemical model of endothelial injury. Thromb Haemost 1998, 79:635-639.
31. Cipollone F, Mezzetti A, Fazia ML, et al.: Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005, 25:1665-1670.
32. Qiu H, Gabrielsen A, Agardh HE, et al.: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 2006, 103:8161-8166.
33. Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
34. Leppert D, Hauser SL, Kishiyama JL, et al.: Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995, 9:1473-1481.
35. Ichiyama T, Kajimoto M, Hasegawa M, et al.: Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp Allergy 2007, 37:608-614.
36. Ahluwalia N, Lin AY, Tager AM, et al.: Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 2007, 179:691-697.
37. Mehrabian M, Allayee H, Wong J, et al.: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002, 91:120-126.
38. Cao RY, Adams MA, Habenicht AJ, Funk CD: Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 2007, 84:34-42.
39. Ghazalpour A, Wang X, Lusis AJ, Mehrabian M: Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics 2006, 173:943-951.
40. Jawien J, Gajda M, Rudling M, et al.: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/ LDLR-double knockout mice. Eur J Clin Invest 2006, 36:141-146.
41. Jawien J, Gajda M, Olszanecki R, Korbut R: BAY × 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2007, 58:583-588.
42. Kaetsu Y, Yamamoro Y, Sugihara S, et al.: Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res 2007, 76:160-166.
43. Porreca E, Di Febbo C, Di Sciullo A, et al.: Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 1996, 76:99-104.
44. Patrignani P, Daffonchio L, Hernandez A, et al.: Release of contracting antacoids by aortae of normal and atherosclerotic rabbits. J Cardiovasc Pharmacol 1992, 20(Suppl 12): S208-S210.
45. Sala A, Rossoni G, Berti F, et al.: Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness. Circulation 2000, 101:1436-1440.
46. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, et al.: Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 2007, 320:108-116.
47. Hakonarson H, Thorvaldsson S, Helgadottir A, et al.: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005, 293:2245-2256.
48. Whatling C, McPheat W, Herslöf M: The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007, 16:1879-1893.
49. Allayee H, Hartiala J, Lee W, et al.: The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 2007, 132:868-874.